Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Ligand Pharmaceuticals Inc.

LGND

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Last trade $295.25
Day change -$6.46 (-2.14%)
Day range $292.86 – $306.61
Volume 154,867
Market cap $6.04B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.04B
Price / earnings
117.27×
Price / book
6.28×
Price / sales
23.78×
EV / sales
28×
EV / EBITDA
108.99×

Profitability

Earnings per share
$2.57
Return on assets
2.3%
Return on equity
5.35%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.17×
Current ratio
1.22×
Quick ratio
1.19×
Cash ratio
0.11×

Cash flow

Price / cash flow
66.3×
Price / free cash flow
66.59×
Free cash flow
$90.63M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LGND, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$78.75M$63.69M$51.72M$59.67M$115.46M$47.63M$45.33M$42.81M
Cost of revenue$12.86M$11.31M$11.37M$2.99M$11.9M$11.17M$13.11M$2.84M
Gross profit$65.89M$52.38M$40.35M$56.67M$103.56M$36.46M$32.23M$39.98M
Selling, general and administrative$72.62M$29.12M$20.84M$25.03M$28.45M$20.18M$18.8M$25.61M
Research and development$2.77M$14.67M$2.15M$3.51M$21.02M$6.57M$50.09M$4.43M
Total operating expenses$81.65M$43.79M$22.98M$42.83M$49.01M$26.74M$68.89M$68.86M
Operating income-$15.76M$8.59M$17.37M$13.84M$54.55M$9.72M-$36.66M-$28.89M
Interest expense-$2.9M-$1.75M-$1.75M-$1.79M-$910K-$1.15M-$867K-$883K
Income before taxes-$44.09M$64.3M-$24.26M$56.78M$141.14M$11.22M-$50.18M-$39.2M
Income taxes-$15.61M$15.8M-$10.91M$12M$23.86M$6.38M-$7.73M-$8.11M
Net income-$28.49M$48.51M-$13.35M$44.78M$117.27M$4.85M-$42.45M-$31.09M
Net income attributable to common shareholders-$28.49M$48.51M-$13.35M$44.78M$117.27M$4.85M-$42.45M-$31.09M
EBITDA-$5.44M$16.81M$25.58M$28.25M$62.82M$18.24M-$27.89M$10.31M
Basic earnings per share-$1.43$2.42-$0.67$2.33$5.99$0.25-$2.21-$1.64
Diluted earnings per share-$1.43$2.22-$0.67$2.09$5.68$0.24-$2.21-$1.67

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Ligand to Participate in September Investor Conferences

Ligand Pharmaceuticals announced that its senior management team will participate in three upcoming investor conferences in September 2026: Wells Fargo Healthcare Conference (September 8), Citi 2026 Biopharma Back to School Conference (September 10), and H.C. Wainwright 28th Annual Global Investment Conference (September 14). The company will host fireside chats and one-on-one meetings with investors at these events.

Investing.com

3 Overlooked Stocks Positioned for the Next Market Rotation

As tech stocks cool and market concentration risks increase, investors should diversify into overlooked sectors. Healthcare, insurance, and regional banking are quietly building momentum. Three recommended stocks are Ligand Pharmaceuticals (royalty-based biotech model with strong growth projections), Aflac (insurance with 44-year dividend history and pet insurance growth), and Atlantic Union Bankshares (regional bank with stable fundamentals and 3.5% dividend yield).

The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.

Benzinga

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.

GlobeNewswire Inc.

Ligand Announces 2026 Investor Day in New York City

Ligand Pharmaceuticals announced it will host an Investor Day in New York City on December 8, 2026, featuring presentations from senior management on the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast will be available through the company's Investor Relations website.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 2, 2010$0.458Jul 1, 2010unknown
Apr 3, 2007$15.00Apr 19, 2007special

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 19, 20101-for-6reverse split